Renal fibrosis: Novel insights into mechanisms and therapeutic targets

Nature Reviews Nephrology

Volumn 6, Issue 11, 2010, Pages 643-656

  Boor, Peter ^a   Ostendorf, Tammo ^a   Floege, Jürgen ^a  

^a RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CD45 ANTIGEN; CHEMOKINE RECEPTOR CCR7; COLLAGEN TYPE 4; COMPLEMENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GREEN FLUORESCENT PROTEIN; HISTONE DEACETYLASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTEGRIN LINKED KINASE; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 13; INTERLEUKIN 4; LAMININ ALPHA4; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA1; NICOTINIC RECEPTOR ALPHA4; ORPHAN NUCLEAR RECEPTOR; OSTEOGENIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIRFENIDONE; PLATELET DERIVED GROWTH FACTOR; RELAXIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN;

APOPTOSIS; AUTOPHAGY; CELL; CELL DAMAGE; CELL DIFFERENTIATION; CELL FUNCTION; CELL PROLIFERATION; CELL TYPE; CLINICAL ASSESSMENT; COMPLEMENT ACTIVATION; DENDRITIC CELL; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; FIBROBLAST; GROWTH DISORDER; IMMUNOHISTOCHEMISTRY; KIDNEY BIOPSY; KIDNEY CELL; KIDNEY FIBROSIS; KIDNEY TUBULE CELL; LIPOID NEPHROSIS; LYMPH VESSEL ENDOTHELIUM; LYMPHOCYTE; MACROPHAGE; MAST CELL; MONOCYTE; MUSCLE FIBER CONTRACTION; MYOFIBROBLAST; NONHUMAN; ONCOGENE H RAS; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEINURIA; REVASCULARIZATION; REVIEW; STEM CELL; UNILATERAL URETERAL OBSTRUCTION; URETER OBSTRUCTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE CELL; WOUND CLOSURE;

FIBROSIS; HUMANS; NEPHRITIS, INTERSTITIAL; RENAL INSUFFICIENCY, CHRONIC;

EID: 78049369136     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2010.120     Document Type: Review

References (167)

1. Zeisberg, M. & Neilson, e. G. Biomarkers for epithelial-mesenchymal transitions. J. Clin. Invest. 119, 1429-1437 (2009).
2. Schlondorff, D. O. Overview of factors contributing to the pathophysiology of progressive renal disease. Kidney Int. 74, 860-866 (2008).
3. Chevalier, R. L. Obstructive nephropathy: towards biomarker discovery and gene therapy Nat Clin. Pract Nephrol. 2, 157-168 (2006).
4. Kaissling, B. & Le Hir, M. The renal cortical interstitium: morphological and functional aspects. Histochem. Cell Biol. 130, 247-262 (2008).
5. Ricardo, S. D., van Goor, H. & eddy, A. A. Macrophage diversity in renal injury and repair. J. Clin. Invest 118, 3522-3530 (2008).
6. Floege, J., eitner, F. & Alpers, C. e. A new look at platelet-derived growth factor in renal disease. J. Am. Soc. Nephrol. 19, 12-23 (2008).
7. Docherty, N. G., O'Sullivan, O. e., Healy, D. A., Fitzpatrick, J. M. & Watson, R. W. evidence that inhibition of tubular cell apoptosis protects against renal damage and development of fibrosis following ureteric obstruction. Am. J. Physiol. Renal Physiol. 290, F4-F13 (2006).
8. Kurts, C., Heymann, F., Lukacs-Kornek, v., Boor, P. & Floege, J. Role of T cells and dendritic cells in glomerular immunopathology. Semin. Immunopathol. 29, 317-335 (2007).
9. Sung, S. S. & Bolton, W. K. T cells and dendritic cells in glomerular disease: the new glomerulotubular feedback loop. Kidney Int 77, 393-399 (2010).
10. Holdsworth, S. R. & Summers, S. A. Role of mast cells in progressive renal diseases. J. Am. Soc. Nephrol. 19, 2254-2261 (2008).
11. Liu, Y. New insights into epithelial-mesenchymal transition in kidney fibrosis. J. Am. Soc. Nephrol. 21, 212-222 (2010).
12. Boor, P, Sebeková, K., Ostendorf, T. & Floege, J. Treatment targets in renal fibrosis. Nephrol. Dial. Transplant. 22, 3391-3407 (2007).
13. Chang, H. Y. et al. Diversity, topographic differentiation, and positional memory in human fibroblasts. Proc. Natl Acad. Sci. USA 99, 12877-12882 (2002).
14. Sorrell, J. M. & Caplan, A. I. Fibroblasts\a diverse population at the center of it all. Int. Rev. Cell Mol. Biol. 276, 161-214 (2009).
15. Hinz, B. The myofibroblast: paradigm for a mechanically active cell. J. Biomech. 43, 146-155 (2010).
16. Eyden, B. The myofibroblast: an assessment of controversial issues and a definition useful in diagnosis and research. Ultrastruct. Pathol. 25, 39-50 (2001).
17. Ru, Y., Eyden, B., Curry, A., McWilliam, L. J. & Coyne, J. D. Actin filaments in human renal tubulo-interstitial fibrosis: significance for the concept of epithelial-myofibroblast transformation. J. Submicrosc. Cytol. Pathol. 35, 221-233 (2003).
18. Muchaneta-Kubara, E. C. & El Nahas, A. M. Myofibroblast phenotypes expression in experimental renal scarring. Nephrol. Dial. Transplant. 12, 904-915 (1997).
19. Lin, S. L., Kisseleva, T., Brenner, D. A. & Duffield, J. S. Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am. J. Pathol. 173, 1617-1627 (2008).
20. Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85-97 (2010).
21. Picard, N., Baum, O., vogetseder, A., Kaissling, B. & Le Hir, M. Origin of renal myofibroblasts in the model of unilateral ureter obstruction in the rat. Histochem. Cell Biol. 130, 141-155 (2008).
22. Crisan, M. et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell 3, 301-313 (2008).
23. Sommer, M. et al. Abnormal growth and clonal proliferation of fibroblasts in an animal model of unilateral ureteral obstruction. Nephron 82, 39-50 (1999).
24. Kilarski, W. W., Samolov, B., Petersson, L., Kvanta, A. & Gerwins, P Biomechanical regulation of blood vessel growth during tissue vascularization. Nat Med. 15, 657-664 (2009).
25. Rohatgi, R. & Flores, D. Intratubular hydrodynamic forces influence tubulointerstitial fibrosis in the kidney. Curr. Opin. Nephrol. Hypertens. 19, 65-71 (2010).
26. Li, L. et al. Aberrant planar cell polarity induced by urinary tract obstruction. Am. J. Physiol. Renal Physiol. 297, F1526-F1533 (2009).
27. Fujigaki, Y. et al. Transient myofibroblast differentiation of interstitial fibroblastic cells relevant to tubular dilatation in uranyl acetate-induced acute renal failure in rats. Virchows Arch. 446, 164-176 (2005).
28. Takeji, M. et al. Smooth muscle alpha-actin deficiency in myofibroblasts leads to enhanced renal tissue fibrosis. J. Biol. Chem. 281, 40193-40200 (2006).
29. Taneda, S. et al. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J. Am. Soc. Nephrol. 14, 2544-2555 (2003).
30. Boor, P et al. PDGF-D inhibition by CR002 ameliorates tubulointerstitial fibrosis following experimental glomerulonephritis. Nephrol. Dial. Transplant 22, 1323-1331 (2007).
31. Ostendorf, T. et al. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J. Am. Soc. Nephrol. 17, 1054-1062 (2006).
32. Kliem, V. et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 49, 666-678 (1996).
33. Alpers, C. E., Seifert, R. A., Hudkins, K. L., Johnson, R. J. & Bowen-Pope, D. F PDGF-receptor localizes to mesangial, parietal epithelial, and interstitial cells in human and primate kidneys. Kidney Int 43, 286-294 (1993).
34. Hawthorne, T. et al. A phase I study of CR002, a fully-human monoclonal antibody against platelet-derived growth factor-D. Int. J. Clin. Pharmacol. Ther. 46, 236-244 (2008).
35. Floege, J. et al. Localization of PDGF alpha-receptor in the developing and mature human kidney. Kidney Int 51, 1140-1150 (1997).
36. Floege, J., Hudkins, K. L., Davis, C. L., Schwartz, S. M. & Alpers, C. E. expression of PDGF alpha-receptor in renal arteriosclerosis and rejecting renal transplants. J. Am. Soc. Nephrol. 9, 211-223 (1998).
37. Eitner, F et al. PDGF-C expression in the developing and normal adult human kidney and in glomerular diseases. J. Am. Soc. Nephrol. 14, 1145-1153 (2003).
38. Eitner, F et al. expression of a novel PDGF isoform, PDGF-C, in normal and diseased rat kidney. J. Am. Soc. Nephrol. 13, 910-917 (2002).
39. Eitner, F et al. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J. Am. Soc. Nephrol. 19, 281-289 (2008).
40. Ding, H. et al. A specific requirement for PDGF-C in palate formation and PDGFR-alpha signaling. Nat Genet 36, 1111-1116 (2004).
41. Huang, X. R., Chung, A. C., Wang, X. J., Lai, K. N. & Lan, H. Y. Mice overexpressing latent TGF-beta1 are protected against renal fibrosis in obstructive kidney disease. Am. J. Physiol. Renal Physiol. 295, F118-F127 (2008).
42. Huang, X. R., Chung, A. C., Zhou, L., Wang, X. J. & Lan, H. Y Latent TGF-beta1 protects against crescentic glomerulonephritis. J. Am. Soc. Nephrol. 19, 233-242 (2008).
43. Zeisberg, M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol. Dial. Transplant 21, 568-573 (2006).
44. Zeisberg, M. et al. Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am. J. Physiol. Renal Physiol. 285, F1060-F1067 (2003).
45. Zeisberg, M. et al. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nat Med. 9, 964-968 (2003).
46. Zeisberg, M., Shah, A. A. & Kalluri, R. Bone morphogenic protein-7 induces mesenchymal to epithelial transition in adult renal fibroblasts and facilitates regeneration of injured kidney. J. Biol. Chem. 280, 8094-8100 (2005).
47. Yanagita, M. Modulator of bone morphogenetic protein activity in the progression of kidney diseases. Kidney Int 70, 989-993 (2006).
48. Tanaka, M. et al. Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome. J. Clin. Invest 120, 768-777 (2010).
49. Grgic, I. et al. Renal fibrosis is attenuated by targeted disruption of KCa3.1 potassium channels. Proc. Natl Acad. Sci. USA 106, 14518-14523 (2009).
50. Bechtel, W. et al. Methylation determines fibroblast activation and fibrogenesis in the kidney. Nat Med. 16, 544-550 (2010).
51. Krupa, A. et al. Loss of MicroRNA-192 promotes fibrogenesis in diabetic nephropathy J. Am. Soc. Nephrol. 21, 438-447 (2010).
52. Kato, M. et al. MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-beta-induced collagen expression via inhibition of e-box repressors. Proc. Natl Acad. Sci. USA 104, 3432-3437 (2007).
53. Wang, Q. et al. MicroRNA-377 is up-regulated and can lead to increased fibronectin production in diabetic nephropathy. FASEB J. 22, 4126-4135 (2008).
54. Rastaldi, M. P et al. epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 62, 137-146 (2002).
55. Hertig, A. et al. early epithelial phenotypic changes predict graft fibrosis. J. Am. Soc. Nephrol. 19, 1584-1591 (2008)
56. Liu, Y epithelial to mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic ntervention. J. Am. Soc. Nephrol. 15, 1-12 (2004).
57. Li, L., Zepeda-Orozco, D., Black, R. & Lin, F Autophagy is a component of epithelial cel fate in obstructive uropathy. Am. J. Pathol. 176, 1767-1778 (2010).
58. Docherty, N. G. et al. Increased e-cadherin expression in the ligated kidney following unilateral ureteric obstruction. Kidney Int 75, 205-213 (2009).
59. Iwano, M. et al. evidence that fibroblasts derive from epithelium during tissue fibrosis. J. Clin. Invest 110, 341-350 (2002).
60. Humphreys, B. D. et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2, 284-291 (2008).
61. Faulkner, J. L., Szcykalski, L. M., Springer, F & Barnes, J. L. Origin of interstitial fibroblasts in an accelerated model of angiotensin II-induced renal fibrosis. Am. J. Pathol. 167, 1193-1205 (2005).
62. Sheerin, N. S. & Sacks, S. H. Leaked protein and interstitial damage in the kidney: s complement the missing link? Clin. Exp. Immunol. 130, 1-3 (2002).
63. Rangan, G. K., Pippin, J. W., Coombes, J. D. & Couser, W. G. C5b-9 does not mediate chronic tubulointerstitial disease in the absence of proteinuria. Kidney Int 67, 492-503 (2005).
64. Rangan, G. K., Pippin, J. W. & Couser, W. G. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 66, 1838-1848 (2004).
65. Boor, P. et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 18, 1508-1515 (2007).
66. Pan, H. et al. Anaphylatoxin C5a contributes to the pathogenesis of cisplatin-induced nephrotoxicity. Am. J. Physiol. Renal Physiol. 296, F496-F504 (2009).
67. Hartleben, B. et al. Autophagy influences glomerular disease susceptibility and maintains podocyte homeostasis in aging mice. J. Clin. Invest 120, 1084-1096 (2010).
68. Kume, S. et al. Calorie restriction enhances cell adaptation to hypoxia through Sirt1-dependent mitochondrial autophagy in mouse aged kidney. J. Clin. Invest 120, 1043-1055 (2010).
69. Cybulsky, A. v. endoplasmic reticulum stress in proteinuric kidney disease. Kidney Int 77, 187-193 (2010).
70. Inagi, R. endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. Nephron Exp. Nephrol. 112, e1-e9 (2009).
71. Periyasamy-Thandavan, S., Jiang, M., Schoenlein, P & Dong, Z. Autophagy: molecular machinery, regulation, and mplications for renal pathophysiology. Am. J. Physiol. Renal Physiol. 297, F244-F256 (2009).
72. Periyasamy-Thandavan, S. et al. Autophagy is cytoprotective during cisplatin injury of renal proximal tubular cells. Kidney Int 74, 631-640 (2008).
73. Pallet, N. et al. Autophagy protects renal tubular cells against cyclosporine toxicity. Autophagy 4, 783-791 (2008).
74. Gozuacik, D. et al. DAP-kinase is a mediator of endoplasmic reticulum stress-induced caspase activation and autophagic cell death. Cell Death Differ. 15, 1875-1886 (2008).
75. Yang, L., Besschetnova, T. Y., Brooks, C. R., Shah, J. v. & Bonventre, J. v. epithelial cell cycle arrest in G2/M mediates kidney fibrosis after injury. Nat Med. 16, 535-543 (2010).
76. Menke, J. et al. CSF-1 signals directly to renal tubular epithelial cells to mediate repair in mice. J. Clin. Invest. 119, 2330-2342 (2009).
77. Ruan, X. Z., varghese, Z. & Moorhead, J. F. An update on the lipid nephrotoxicity hypothesis. Nat Rev. Nephrol. 5, 713-721 (2009).
78. Cho, K. H., Kim, H. J., Kamanna, v. S. & vaziri, N. D. Niacin improves renal lipid metabolism and slows progression in chronic kidney disease. Biochim. Biophys. Acta 1800, 6-15 (2010).
79. Cho, K. H., Kim, H. J., Rodriguez-Iturbe, B. & vaziri, N. D. Niacin ameliorates oxidative stress, inflammation, proteinuria, and hypertension in rats with chronic renal failure. Am. J. Physiol. Renal Physiol. 297, F106-F113 (2009).
80. Kim, H. J., Moradi, H., Yuan, J., Norris, K. & vaziri, N. D. Renal mass reduction results in accumulation of lipids and dysregulation of lipid regulatory proteins in the remnant kidney. Am. J. Physiol. Renal Physiol. 296, F1297-F1306 (2009).
81. Wu, J. et al. Peroxisome proliferator-activated receptors and renal diseases. Front Biosci. 14, 995-1009 (2009).
82. Toblli, J. E. et al. Antifibrotic effects of pioglitazone on the kidney in a rat model of type 2 diabetes mellitus. Nephrol. Dial. Transplant 24, 2384-2391 (2009).
83. Kawai, T. et al. PPAR-gamma agonist attenuates renal interstitial fibrosis and inflammation through reduction of TGF-beta. Lab. Invest 89, 47-58 (2009).
84. Higgins, D. F., Kimura, K., Iwano, M. & Haase, V. H. Hypoxia-inducible factor signaling in the development of tissue fibrosis. Cell Cycle 7, 1128-1132 (2008).
85. Kimura, K. et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am. J. Physiol. Renal Physiol. 295, F1023-F1029 (2008).
86. Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J. Clin. Invest 117, 3810-3820 (2007).
87. Zeisberg, E. M., Potenta, S. E., Sugimoto, H., Zeisberg, M. & Kalluri, R. Fibroblasts in kidney fibrosis emerge via endothelial-to-mesenchymal transition. J. Am. Soc. Nephrol. 19, 2282-2287 (2008).
88. Li, J., Qu, X. & Bertram, J. F. endothelial-myofibroblast transition contributes to the early development of diabetic renal interstitial fibrosis in streptozotocin-induced diabetic mice. Am. J. Pathol. 175, 1380-1388 (2009).
89. Zhou, X. J. et al. The aging kidney. Kidney Int 74, 710-720 (2008).
90. Wilkinson, L. et al. Loss of renal microvascular integrity in postnatal Crim1 hypomorphic transgenic mice. Kidney Int 76, 1161-1171 (2009).
91. Hakroush, S. et al. effects of increased renal tubular vascular endothelial growth factor (veGF) on fibrosis, cyst formation, and glomerular disease. Am. J. Pathol. 175, 1883-1895 (2009).
92. Sakai, N. et al. Secondary lymphoid tissue chemokine (SLC/CCL21)/CCR7 signaling regulates fibrocytes in renal fibrosis. Proc. Natl Acad. Sci. USA 103, 14098-14103 (2006).
93. Niedermeier, M. et al. CD4+ T cells control the differentiation of Gr1+ monocytes into fibrocytes. Proc. Natl Acad. Sci. USA 106, 17892-17897 (2009).
94. Sakai, N. et al. Fibrocytes are involved in the pathogenesis of human chronic kidney disease. Hum. Pathol. 41, 672-678 (2010).
95. Pilling, D., Fan, T., Huang, D., Kaul, B. & Gomer, R. H. Identification of markers that distinguish monocyte-derived fibrocytes from monocytes, macrophages, and fibroblasts. PLoS ONE 4, e7475 (2009).
96. Wynn, T. A. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev. Immunol. 4, 583-594 (2004).
97. Shao, D. D., Suresh, R., vakil, v., Gomer, R. H. & Pilling, D. Pivotal advance: Th-1 cytokines inhibit, and Th-2 cytokines promote fibrocyte differentiation. J. Leukoc. Biol. 83, 1323-1333 (2008).
98. Lin, S. L., Castaño, A. P, Nowlin, B. T., Lupher, M. L. Jr & Duffield, J. S. Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J. Immunol. 183, 6733-6743 (2009).
99. Roufosse, C. et al. Bone marrow-derived cells do not contribute significantly to collagen synthesis in a murine model of renal fibrosis. J. Am. Soc. Nephrol. 17, 775-782 (2006).
100. Broekema, M. et al. Bone marrow-derived myofibroblasts contribute to the renal interstitial myofibroblast population and produce procollagen I after ischemia/reperfusion in rats. J. Am. Soc. Nephrol. 18, 165-175 (2007).
101. Henderson, N. C. et al. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 172, 288-298 (2008).
102. Henderson, N. C. & Sethi, T. The regulation of inflammation by galectin-3. Immunol. Rev. 230, 160-171 (2009).
103. Ma, F. Y., Liu, J., Kitching, A. R., Manthey, C. L. & Nikolic-Paterson, D. J. Targeting renal macrophage accumulation via c-fms kinase reduces tubular apoptosis but fails to modify progressive fibrosis in the obstructed rat kidney. Am. J. Physiol. Renal Physiol. 296, F177-F185 (2009).
104. Lin, S. L. et al. Macrophage Wnt7b is critical for kidney repair and regeneration. Proc. Natl Acad. Sci. USA 107, 4194-4199 (2010).
105. Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science 327, 656-661 (2010).
106. Nishida, M. & Hamaoka, K. Macrophage phenotype and renal fibrosis in obstructive nephropathy. Nephron Exp. Nephrol. 110, e31-e36 (2008).
107. Wang, Y et al. By homing to the kidney, activated macrophages potently exacerbate renal injury. Am. J. Pathol. 172, 1491-1499 (2008).
108. Nishida, M. et al. Adoptive transfer of macrophages ameliorates renal fibrosis in mice. Biochem. Biophys. Res. Commun. 332, 11-16 (2005).
109. Krüger, T. et al. Identification and functional characterization of dendritic cells in the healthy murine kidney and in experimental glomerulonephritis. J. Am. Soc. Nephrol. 15, 613-621 (2004).
110. Macconi, D. et al. Proteasomal processing of albumin by renal dendritic cells generates antigenic peptides. J. Am. Soc. Nephrol. 20, 123-130 (2009).
111. Heymann, F. et al. Kidney dendritic cell activation is required for progression of renal disease in a mouse model of glomerular injury. J. Clin. Invest 119, 1286-1297 (2009).
112. Sakamoto, I. et al. Lymphatic vessels develop during tubulointerstitial fibrosis. Kidney Int 75, 828-838 (2009).
113. Matsui, K. et al. Lymphatic microvessels in the rat remnant kidney model of renal fibrosis: aminopeptidase p and podoplanin are discriminatory markers for endothelial cells of blood and lymphatic vessels. J. Am. Soc. Nephrol. 14, 1981-1989 (2003).
114. Kriz, W. & LeHir, M. Pathways to nephron loss starting from glomerular diseases\insights from animal models. Kidney Int 67, 404-419 (2005).
115. Zhang, T. et al. Disturbance of lymph circulation develops renal fibrosis in rats with or without contralateral nephrectomy. Nephrology (Carlton) 13, 128-138 (2008).
116. Zhang, T et al. Functional, histological and biochemical consequences of renal lymph disorder in mononephrectomized rats. J. Nephrol. 22, 109-116 (2009).
117. Kerjaschki, D. et al. Lymphatic neoangiogenesis in human kidney transplants is associated with mmunologically active lymphocytic infiltrates. J. Am. Soc. Nephrol. 15, 603-612 (2004).
118. Stuht, S. et al. Lymphatic neoangiogenesis in human renal allografts: results from sequential protocol biopsies. Am. J. Transplant. 7, 377-384 (2007).
119. El-Koraie, A. F., Baddour, N. M., Adam, A. G., El Kashef, E. H. & El Nahas, A. M. Role of stem cell factor and mast cells in the progression of chronic glomerulonephritides. Kidney Int 60, 167-172 (2001).
120. Roberts, I. S. & Brenchley, P e. Mast cells: the forgotten cells of renal fibrosis. J. Clin. Pathol. 53, 858-862 (2000).
121. Kondo, S. et al. Role of mast cell tryptase in renal interstitial fibrosis. J. Am. Soc. Nephrol. 12, 1668-1676 (2001).
122. Timoshanko, J. R., Kitching, R., Semple, T. J., Tipping, P G. & Holdsworth, S. R. A pathogenetic role for mast cells in experimental crescentic glomerulonephritis. J. Am. Soc. Nephrol. 17, 150-159 (2006).
123. Kanamaru, Y et al. Mast cell-mediated remodeling and fibrinolytic activity protect against fatal glomerulonephritis. J. Immunol. 176, 5607-5615 (2006).
124. Miyazawa, S. et al. Role of mast cells in the development of renal fibrosis: use of mast cell-deficient rats. Kidney Int 65, 2228-2237 (2004).
125. Hochegger, K. et al. Role of mast cells in experimental anti-glomerular basement membrane glomerulonephritis. Eur. J. Immunol. 35, 3074-3082 (2005).
126. Kim, D. H. et al. Mast cells decrease renal fibrosis in unilateral ureteral obstruction. Kidney Int 75, 1031-1038 (2009).
127. Silver, R. B. et al. Mast cells: a unique source of renin. Proc. Natl Acad. Sci. USA 101, 13607-13612 (2004).
128. Fan, Y. Y. et al. Contribution of chymase-dependent angiotensin II formation to the progression of tubulointerstitial fibrosis in obstructed kidneys in hamsters. J. Pharmacol. Sci. 111, 82-90 (2009).
129. Shweke, N. et al. Tissue transglutaminase contributes to interstitial renal fibrosis by favoring accumulation of fibrillar collagen through TGF-beta activation and cell infiltration. Am. J. Pathol. 173, 631-642 (2008).
130. Huang, L. et al. Transglutaminase inhibition ameliorates experimental diabetic nephropathy Kidney Int. 76, 383-394 (2009).
131. Abrass, C. K., Hansen, K. M. & Patton, B. L. Laminin alpha4-null mutant mice develop chronic kidney disease with persistent overexpression of platelet-derived growth factor. Am. J. Pathol. 176, 839-849 (2010).
132. Xie, P et al. C/eBP-beta modulates transcription of tubulointerstitial nephritis antigen in obstructive uropathy. J. Am. Soc. Nephrol. 20, 807-819 (2009).
133. Ramachandra Rao, S. P et al. Pirfenidone is renoprotective in diabetic kidney disease. J. Am. Soc. Nephrol. 20, 1765-1775 (2009).
134. Takakuta, K. et al. Renoprotective properties of pirfenidone in subtotally nephrectomized rats. Eur. J. Pharmacol. 629, 118-124 (2010).
135. Cho, M. E. & Kopp, J. B. Pirfenidone: an anti-fibrotic therapy for progressive kidney disease. Expert Opin. Investig. Drugs 19, 275-283 (2010).
136. Cho, M. E., Smith, D. C., Branton, M. H., Penzak, S. R. & Kopp, J. B. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin. J. Am. Soc. Nephrol. 2, 906-913 (2007).
137. Cook, H. T. The origin of renal fibroblasts and progression of kidney disease. Am. J. Pathol. 176, 22-24 (2010).
138. Little, M. H. & Bertram, J. F. Is there such a thing as a renal stem cell? J. Am. Soc. Nephrol. 20, 2112-2117 (2009).
139. Hopkins, C., Li, J., Rae, F. & Little, M. H. Stem cell options for kidney disease. J. Pathol. 217, 265-281 (2009).
140. Psihogios, N. G. et al. evaluation of tubulointerstitial lesions' severity in patients with glomerulonephritides: an NM R-based metabonomic study. J. Proteome Res. 6, 3760-3770 (2007).
141. Nickolas, T. L., Barasch, J. & Devarajan, P. Biomarkers in acute and chronic kidney disease. Curr. Opin. Nephrol. Hypertens. 17, 127-132 (2008). (Pubitemid 351253035)
142. Tanaka, T. et al. Urinary L-type fatty acid-binding protein can reflect renal tubulointerstitial injury. Am. J. Pathol. 174, 1203-1211 (2009).
143. Yamamoto, T. et al. Renal L-type fatty acid\binding protein in acute ischemic injury. J. Am. Soc. Nephrol. 18, 2894-2902 (2007).
144. Negishi, K. et al. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int. 73, 1374-1384 (2008).
145. Miranda, K. C. et al. Nucleic acids within urinary exosomes/microvesicles are potential biomarkers for renal disease. Kidney Int. 78, 191-199 (2010).
146. Sato, Y. et al. Urine podocyte mRNAs mark progression of renal disease. J. Am. Soc. Nephrol. 20, 1041-1052 (2009).
147. Hartono, C., Muthukumar, T. & Suthanthiran, M. Noninvasive diagnosis of acute rejection of renal allografts. Curr. Opin. Organ Transplant 15, 35-41 (2010).
148. Ghoul, B. E. et al. Urinary procollagen II aminoterminal propeptide (PIIINP): a fibrotest for the nephrologist. Clin. J. Am. Soc. Nephrol. 5, 205-210 (2010).
149. Ju, W. et al. Renal gene and protein expression signatures for prediction of kidney disease progression. Am. J. Pathol. 174, 2073-2085 (2009).
150. Sato, Y et al. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol. 26, 431-442 (2008).
151. Choi, H. S. et al. Renal clearance of quantum dots. Nat Biotechnol. 25, 1165-1170 (2007).
152. Jones, L. K. et al. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis. Nephrol. Dial. Transplant 24, 3024-3032 (2009).
153. Li, Y et al. Inhibition of integrin-linked kinase attenuates renal interstitial fibrosis. J. Am. Soc. Nephrol. 20, 1907-1918 (2009).
154. Zhang, G. et al. A novel signaling pathway: fibroblast nicotinic receptor alpha1 binds urokinase and promotes renal fibrosis. J. Biol. Chem. 284, 29050-29064 (2009).
155. Pang, M. et al. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy Am. J. Physiol. Renal Physiol. 297, F996-F1005 (2009).
156. Noh, H. et al. Histone deacetylase-2 is a key regulator of diabetes-and transforming growth factor-beta1-induced renal injury. Am. J. Physiol. Renal Physiol. 297, F729-F739 (2009).
157. Grande, M. T. et al. Targeted genomic disruption of H-ras and N-ras has no effect on early renal changes after unilateral ureteral ligation. World J. Urol. doi:10.1007/s00345-009-0399-8.
158. Grande, M. T. et al. Deletion of H-Ras decreases renal fibrosis and myofibroblast activation following ureteral obstruction in mice. Kidney Int. 77, 509-518 (2010).
159. Liao, T. D. et al. N-acetyl-seryl-aspartyl-lysyl-proline attenuates renal injury and dysfunction in hypertensive rats with reduced renal mass: council for high blood pressure research. Hypertension 55, 459-467 (2010).
160. Kassiri, Z. et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J. Am. Soc. Nephrol. 20, 1223-1235 (2009).
161. Jung, G. S. et al. The orphan nuclear receptor SHP attenuates renal fibrosis. J. Am. Soc. Nephrol. 20, 2162-2170 (2009).
162. Hewitson, T. D. et al. endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 148, 660-669 (2007).
163. Teerlink, J. R. et al. Relaxin for the treatment of patients with acute heart failure (Pre-ReLAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 373, 1429-1439 (2009).
164. Yuen, D. A. et al. Culture-modified bone marrow cells attenuate cardiac and renal injury in a chronic kidney disease rat model via a novel antifibrotic mechanism. PLoS ONE 5, e9543 (2010).
165. Benigni, A., Morigi, M. & Remuzzi, G. Kidney regeneration. Lancet 375, 1310-1317 (2010).
166. Sakairi, T et al. Nestin expression in the kidney with an obstructed ureter. Kidney Int. 72, 307-318 (2007).
167. Nguyen T. Q. et al. CTGF inhibits BMP-7 signaling in diabetic nephropathy. J. Am. Soc. Nephrol. 19, 2098-2107 (2008).